VIP (Vasoactive Intestinal Peptide)
28-Residue Neuropeptide
Vasoactive intestinal peptide — 28-residue neuropeptide studied for smooth-muscle relaxation and mast-cell stabilization research. Available in 5 mg and 10 mg.
Recovery & Healing
Category
From $71.99
Price
Research
Grade
Price
From $71.99
✓ 10% off via PeptidesMuscle
Suggested Protocol
Pilot-scale cadences mirror the published or community source — intranasal microgram dosing multiple times daily for CIRS protocols, or IV/inhaled routes at research-specific doses for pulmonary/vascular work. The advantage of the 5mg format is validating cadence on a short horizon before moving to the 10mg extended format if the research plan requires continuity.
This 5mg vial is the pilot-study format of Vasoactive Intestinal Peptide. Where the 10mg vial is sized for extended multi-month research arcs, the 5mg fits shorter replication windows: pilot CIRS-protocol runs, bench-scale VPAC1/VPAC2 binding work, or short-horizon trials where the researcher wants to validate a cadence before committing to the larger format.
Reported Outcomes
5mg pilot-study format of native 28-residue VIP
Identical chemistry to 10mg vial — different research horizon
Suited to short-cadence CIRS protocol pilot runs
Fits bench-scale VPAC1/VPAC2 binding replication work
Common entry vial for intranasal titration protocols
Limits single-batch exposure during cadence validation
Format Logic
Why Pilot-Scale First
Research peptides with broad physiological portfolios benefit from cadence validation on a short horizon before committing to a long study arc. The 5mg format lets a researcher prove out the reconstitution handling, the route selection, and the dosing rhythm across one clean vial before stepping up to extended work on the 10mg.
Identical Pharmacology
Chemistry Does Not Change With Vial Size
The 5mg and 10mg VIP vials are the same molecule — the 28-residue Said-Mutt peptide with VPAC1/VPAC2 affinity and Gαs coupling. Any mechanism note that applies to the 10mg applies equally here. The decision between them is about research horizon, not about the molecule's behaviour.
CIRS Protocol Fit
Entry-Point Vial for Intranasal Protocol Work
The Shoemaker intranasal-VIP community protocol titrates over weeks, and most researchers approaching it for the first time want to validate that the route, the device, and the cadence work in their hands before ordering longer-horizon material. The 5mg is the natural entry point for that validation stage.
Specifications
| Product | VIP (Vasoactive Intestinal Peptide) |
|---|---|
| Category | Recovery & Healing |
| Format | Lyophilized powder |
| Price | From $71.99 |
Pairs Well With
Research Protocol
Pilot-scale cadences mirror the published or community source — intranasal microgram dosing multiple times daily for CIRS protocols, or IV/inhaled routes at research-specific doses for pulmonary/vascular work. The advantage of the 5mg format is validating cadence on a short horizon before moving to the 10mg extended format if the research plan requires continuity.
VIP (Vasoactive Intestinal Peptide) — FAQs
Related Recovery & Healing Research
View All
Prostamax 20mg
Prostamax is the prostate-positioned synthetic tetrapeptide in the Khavinson series, successor to the earlier bovine-prostate extract Prostatilen — a drug with a substantial Soviet-era urology track record that informs how the synthetic representative is studied today.
Bacteriostatic Water USP 30mL
USP-grade sterile water with 0.9% benzyl alcohol — the pharmacopeia-verified reconstitution solvent. Identical function to standard bacteriostatic water but manufactured and tested against United States Pharmacopeia monograph standards.
Livagen 20mg
Livagen is a Lys-Glu-Asp-Ala (KEDA) tetrapeptide in the Khavinson series targeted to hepatic tissue — a synthetic successor to the calf-liver peptide extract Epithalon, positioned for research on hepatocyte function in ageing.
